Azione 603739 QINGDAO VLAND BIOTECH INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Qingdao Vland Biotech INC.

Azioni

603739

CNE100003GX8

Prezzo di chiusura Shanghai S.E.
Altri mercati azionari
 00:00:00 08/07/2024 		Variaz. 5gg Var. 1 gen.
12,26 CNY -3,46% Grafico intraday di Qingdao Vland Biotech INC. -7,33% -19,45%
07/05 Le azioni cinesi sono in calo; le azioni di Hong Kong scendono dopo una striscia vincente di 10 giorni RE
25/04 Qingdao Vland Biotech INC. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024 CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
China stocks edge down; HK shares fall after 10-day winning streak
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2023
Qingdao Vland Biotech Forms Chinese JV With Germany’s Evonik
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2023
Qingdao Vland Biotech INC. completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders.
Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan
Qingdao Vland Biotech INC. signed a share transfer agreement to acquire a 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders for CNY 91.8 million.
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2023
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2022
Qingdao Vland Biotech's Joint Venture to Invest Up to 400 Million Yuan for Probiotic Food Plant
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2022
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2021
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2021
Weifang Weizhilan Biological Technology Co., Ltd. announced that it expects to receive CNY 182.888 million in funding from Qingdao Vland Biotech INC., Archer Daniels Midland Singapore Pte Ltd.
Archer Daniels Midland : to Create Human Probiotics Joint Venture With Qingdao Vland Biotech Group
Qingdao Vland Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione 603739
  4. Notizie Qingdao Vland Biotech INC.
  5. Altre lingue